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Human -Enolase From Endothelial Cells as a
Target Antigen of Anti–Endothelial Cell Antibody
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Objective. To identify and recombine a protein of
the human dermal microvascular endothelial cell (HD-
MEC) that specifically reacts with anti–endothelial cell
antibody (AECA) in the serum of patients with Behc¸et’s
disease (BD), and to evaluate the usefulness of this
protein in BD.
Methods. The proteomics technique, with
2-dimensional gel electrophoresis and matrix-assisted
laser desorption ionizationtime-of-flight (MALDI-
TOF) mass spectrometry, was used to identify and
recombine HDMEC antigen. Western blotting and
enzyme-linked immunosorbent assay (ELISA) of recom-
binant protein isolated by gene cloning were performed
on serum from healthy controls, patients with BD, and
patients with other rheumatic diseases (rheumatoid
arthritis, systemic lupus erythematosus, and Wegener’s
granulomatosis).
Results. Eighteen of 40 BD patients had serum
IgM antibody to HDMEC antigen. The purified protein
that reacted with AECA in BD patient sera was found to
be -enolase by 2-dimensional gel electrophoresis fol-
lowed by immunoblotting and MALDI-TOF mass spec-
trometry. Recombinant -enolase protein was isolated
and refined by gene cloning. On Western blots, AECA-
positive IgM from the sera of patients with active BD
reacted strongly with recombinant human -enolase.
BD patient sera positive for anti–-enolase did not react
with human -enolase. On dot-blotting, reactivity to
human -enolase was detected only in the IgM-positive
group. Fifteen of the 18 AECA-positive sera that were
positive for the HDMEC antigen showed reactivity to
recombinant -enolase IgM antibody by ELISA.
Conclusion. The -enolase protein is the target
protein of serum AECA in BD patients. This is the first
report of the presence of IgM antibodies to -enolase in
endothelial cells from the serum of BD patients. Al-
though further studies relating this protein to the
pathogenesis of BD will be necessary, -enolase and its
antibody may prove useful in the development of new
diagnostic and treatment modalities in BD.
Behc¸et’s disease (BD) is a chronic, multisystem
disorder characterized by a recurrent inflammatory re-
action. Serious complications, such as blindness or intes-
tinal perforations, can occur. Because of the lack of
definitive diagnostic tests for BD, the diagnosis is based
solely on the clinical manifestations. The pathogenesis of
BD remains obscure. Clinically, BD patients experience
recurrent thrombophlebitis, thrombosis, and cutaneous
vasculitis (1). Histopathologic changes consisting of
perivascular mononuclear cellular infiltrates, endothe-
lial cell swelling or necrosis, partial obliteration of the
vessel lumen, and occasional fibrinoid necrosis of vessels
have been observed. In more severe forms, small to
medium-sized arteries, veins, and capillaries may be
affected by a necrotizing or granulomatous vasculitis (2,3).
Anti–endothelial cell antibody (AECA) was first
detected in various inflammatory diseases by indirect
immunofluorescence using a mouse kidney substrate (4).
AECA has been demonstrated in the serum of patients
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with systemic lupus erythematosus (SLE), rheumatoid
arthritis (RA), mixed connective tissue disease, sclero-
derma, and dermatomyositis, as well as patients with
Wegener’s granulomatosis (WG), primary retinal vascu-
litis, Kawasaki disease, acute hemolytic uremic syndrome,
diabetes mellitus, organ transplants, hypoparathyroid-
ism, multiple sclerosis, thrombotic thrombocytopenic
purpura, angioedema, and Buerger’s disease (5,6).
AECA has also been demonstrated in the serum of BD
patients (7–10) and has been associated with disease
activity and vasculitis symptoms (6,7).
Even though a large number of molecules on the
surface of endothelial cells have been characterized,
only a few reports have studied the characteristics of the
antigen recognized by AECA. In a previous study (9), we
used an enzyme-linked immunosorbent assay (ELISA)
to detect circulating antibodies against human dermal
microvascular endothelial cells (HDMECs) in the serum
of patients with BD. Serum IgM antibody against HD-
MEC was detected in 49 of 131 BD patients. On
Western blots, IgM-positive BD serum reacted with the
44–50-kd HDMEC surface antigen, whereas IgM-
positive SLE serum reacted with the 81-kd HDMEC
surface antigen (9).
Proteomics is a field of science that evaluates a
large number of proteins expressed from a given cell line
or organism. The technology of proteomics has been
used as a method of discovering the target protein
specific to a particular disease by searching for the
expression or modification of the protein (11,12). To
characterize the AECA-binding HDMEC antigen,
which is closely related to the pathogenesis of BD, we
first identified a target protein by 2-dimensional (2-D)
gel electrophoresis and immunoblotting, and then
searched for a similar protein after the amino acids were
sequenced by mass spectrometry. We next searched for
the DNA sequence of the target protein at the National
Center for Biotechnology Information (NCBI) and pu-
rified the recombinant target protein by gene cloning.
We then investigated the reactivities of the recombinant
target protein in BD.
PATIENTS AND METHODS
Patients. This study included 40 BD patients who
fulfilled the diagnostic criteria of the International Study
Group for BD (13). All patients had active disease, meeting at
least 2 major criteria with or without any number of minor
criteria. Sera from 40 healthy volunteer donors, 6 patients with
RA, 5 patients with SLE, and 2 patients with WG were used as
controls. We measured rheumatoid factor (RF), antinuclear
antibody (ANA), and antineutrophil cytoplasmic antibody
(ANCA) in all serum samples from BD patients.
Isolation and culture of HDMECs. HDMECs were
isolated from human newborn foreskins by a previously re-
ported technique (14). Briefly, the tissue was cut into 5-mm2
sections. The sections were incubated for 40 minutes at 37°C in
trypsin solution and then washed 3 times in phosphate buff-
ered saline (PBS). Pressure was initially applied to the center
of each tissue section, and the released cells were pushed
outward, toward the periphery of the tissue section and into
the medium. The primary isolated cells were collected by
centrifugation (800g for 1 minute) and resuspended in endo-
thelial basal media (Clonetics, San Diego, CA), with 5 ng/ml of
epidermal growth factor (Clonetics), 1 g/ml of hydrocortisone
acetate (Sigma, St. Louis, MO), 5  10–5M dibutyryl cAMP
(Sigma), 100 units/ml of penicillin, 100 g/ml of streptomycin,
250 g/ml of amphotericin B (Sigma), and 30% human serum
(Irvine Scientific, Santa Ana, CA).
The resultant cell cultures were free of contaminating
fibroblasts, as assessed by morphologic and immunologic cri-
teria. Until required for experiments, cells from the second
passage were cultured in endothelial basal medium (Clonetics)
containing 5 g of human epidermal growth factor, 1 g/ml of
hydrocortisone acetate, 5  10–5M dibutyryl cAMP, 100
units/ml of penicillin, 100 g/ml of gentamicin, 250 g/ml of
amphotericin B, and 2% fetal bovine serum.
ELISA. HDMECs were plated in microtiter plates and
allowed to grow to confluence over 24 hours. The plates were
washed 3 times with 0.05% PBS–Tween 20 (PBST) to block
nonspecific binding. Then, 100 l of sera from normal controls
and BD patients, diluted 1:50 in Hanks’ balanced salt solution
(HBSS) with divalent cations (Irvine Scientific) and 1% bovine
serum albumin (BSA; Sigma), was added to each well of
unfixed HDMEC, and the plates were incubated for 1 hour at
37°C. Peroxidase-conjugated goat anti-human IgG or IgM
diluted 1:1,000 in HBSS with divalent cations and 1% BSA was
added to each well, and the plates were incubated for 1 hour at
37°C. Three wells containing diluent only were used as blanks
to provide a background level.
Antibody binding was quantified colorimetrically by
adding tetramethylbenzidine (Sigma) as substrate. One micro-
liter of 30% H2O2 was added immediately prior to use. The
chromogenic reaction was stopped with 8N H2SO4, and the
plates were read spectrophotometrically at 450 nm on an
ELISA reader (Dynatech, Alexandria, VA). Positivity was
defined as an optical density (OD) greater than the mean plus
3 SD for the 40 normal control sera.
Gel electrophoresis and immunoblotting of HDMEC
antigen. HDMEC antigen in EDTA/BSA was dissolved in
buffer (1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA, and
1% Triton X-100) on ice for 30 minutes. After centrifugation
at 10,000g for 30 minutes at 4°C, the supernatant was collected
and mixed with the same amount of sample buffer. Samples
were then loaded into the wells of a 10% polyacrylamide gel,
and electrophoresis was performed at a fixed current for 45–90
minutes. The separated gel was transferred to a nitrocellulose
membrane, washed with 0.05% PBST, and incubated overnight
at 4°C in blocking buffer. After a second overnight incubation
at 4°C (with gentle agitation) in sera from normal controls and
BD patients, diluted 1:50 with primary antibody dilution
buffer, the membrane was washed 3 times with PBST and then
incubated with peroxidase-conjugated goat anti-human IgM
for 2 hours. After washing with PBST, diaminobenzidine with
2026 LEE ET AL
30% H2O2 was added, and the membrane was incubated at
37°C for 10 minutes.
Fractionation of IgM from the AECA-positive BD
patient sera and confocal laser microscopy. The column was
filled with PBS treated with Ultrogel AcA 34 (Sigma). Serum
was passed through the column, and 4 fractions were collected.
Reaction of the isolated IgM antibody against HDMEC anti-
gen was confirmed by gel electrophoresis and immunoblotting
as described above. Cultured HDMECs were trypsinized and
replated in 8-well chamber slides (Becton Dickinson, Moun-
tain View, CA). The fractionated IgM obtained from the sera
of normal controls and AECA-positive BD patients (diluted
1:20 in HBSS with divalent cations and 1% BSA) was added to
unfixed HDMEC monolayers and incubated with fluorescein
isothiocyanate–conjugated goat anti-human IgM. The slides
were washed and evaluated for fluorescence using a confocal
laser microscope (TCSNT; Leica, Heidelberg, Germany).
Protein preparation. Cells were washed twice with
ice-cold PBS and harvested using homemade scrapers to
prepare the supernatant. The resulting pellets were resus-
pended in 500 l of solubilization buffer consisting of 7M urea,
2M thiourea, 4% CHAPS, 2 mM tributylphosphosine (TBP),
0.5% carrier ampholytes, 40 mM Tris, and 0.001% bromphenol
blue. Samples were mixed on a vortex mixer for 30 seconds and
ultrasonicated using an Ultrasonic Processor XL (XL2020;
Misonix, New York, NY); this sonication procedure was
repeated 4 times. Nucleic acids were digested with endonucle-
ase (Sigma) using 150 units/ml of sample for 30 minutes at
room temperature. Samples were centrifuged at 10,000g for 10
minutes and supernatants were collected. Extra protein ex-
tracts were stored at –80°C until used.
Two-dimensional gel electrophoresis. Rehydration of
supernatants was performed using an 18-cm, pH 3–10, linear
immobilized pH gradient (IPG) strip (Amersham Pharmacia
Biotech, Piscataway, NJ) for 24 hours. Isoelectric focusing (IEF)
was performed with rehydrated IPG strips using a Protean IEF
cell (Bio-Rad, Hercules, CA) for the appropriate time. After IEF,
the IPG strips were equilibrated for 25 minutes in buffer consist-
ing of 6M urea, 2% sodium dodecyl sulfate (SDS), 5M Tris, 20%
glycerol, 25% acrylamide, and 200 mM TBP.
To make the polyacrylamide gel, a 9% buffer solution
containing 1.875M Tris buffer, 40% stock acrylamide, distilled
water, 16% buffer solution, 40% stock acrylamide, and 50%
glycerol was mixed, and a 9–16% gradient polyacrylamide gel
was prepared. After adding agarose buffer, which included
0.5% agarose and 0.001% bromphenol blue dye, the IPG strip
was embedded, and cathode-running buffer (24.8 mM Tris, 192
mM glycine, and 0.1% SDS) was added. Gels were run initially
at 3 mA/gel for 2 hours and then at 18 mA/gel for 16 hours.
Two-dimensional immunoblotting and isolation of
protein spots. The gel was transferred to a nitrocellulose
membrane by semidry transfer (Bio-Rad) at 500 mA for 2
hours. Immunoblotting was performed with isolated AECA
IgM antibody from the serum of BD patients. The protein spot
was separated with a clean razor blade and dehydrated in 50
mM ammonium bicarbonate solution for 5 minutes. After
dehydration in acetonitrile in a speedback evaporator, the
protein had dried sufficiently. After treatment in 25 mM
ammonium bicarbonate solution containing 0.1 g of trypsin at
37°C for 16 hours, tryptic peptides were eluted several times
and then thoroughly dried in a speedback evaporator.
Peptide fingerprint by mass spectrometry. Samples
mixed with saturated -cyano-4-hydroxycinnamic acid were
dropped onto a matrix-assisted laser desorption ionization
(MALDI) plate and dried at room temperature. The mass
spectrum was obtained by averaging 40–50 individual laser
shots, using a MALDI Reflectron time of flight instrument
(Micromass, Manchester, UK). The autolytic peptide peak
(m/z 842.50 and 2211.10) of bovine trypsin was used as an
internal standard.
Scanning the data for a peptide fingerprint. We en-
tered our protein mass data into the MS-Fit program, a
peptide mass fingerprinting tool provided by the University of
California, San Francisco (UCSF) (available at http://
prospector.ucsf.edu/ucsfhtml4.0/msfit.htm), which uses an
NCBI scanning algorithm, to search for the identity of the
protein. The error limit was within 50 parts per million.
Synthesis of complementary DNA (cDNA) by reverse
transcription–polymerase chain reaction (RT-PCR). Whole
RNA was isolated from cultured HDMECs using TRIzol
reagent, based on the acid guanidinium thiocyanate–phenol–
chloroform extraction method according to the manufacturer’s
instructions (Invitrogen Life Technologies, Carlsbad, CA).
First-strand cDNA was synthesized from 10 g of total RNA
using the Superscript II preamplification system (Invitrogen
Life Technologies). Whole RNA was mixed with random
hexamer (Promega, Madison, WI), dNTPs, buffer, dithiothre-
itol, and RNase to proper density. After adding Superscript II
reverse transcriptase, samples were incubated at 42°C for 1
hour. Synthesized first-strand cDNA was then mixed with
dNTPs, MgCl2, and buffer. DNA polymerase and primer
corresponding to the protein were mixed. Double-stranded
cDNA was synthesized by 40 cycles of denaturation at 94°C for
2 minutes, annealing at 55°C for 1 minute, and extension at
72°C for 2 minutes.
Primers were designed according to the coding se-
quences for human -enolase, and Bam HI and Xho I restric-
tion sites were placed at their respective terminal ends to facilitate
subcloning of the PCR product into the expression vector
pGEX-4T-1. Primer sequences were 5-CAGTTGGATCC-
TCTATTCTCAAGATCCATGCCA-3 for the sense primer
and 5-ATCCTCGAGTTACTTGGCCAAGGGRTTTCTG-
AAGTTCCTG-3 for the antisense primer.
Subcloning of cDNA. Amplification products were
separated on agarose gels, and the band of the desired size was
excised and purified using 6N NaI and GlassMilk (Invitrogen,
Carlsbad, CA). The GlassMilk was precipitated by centrifuga-
tion at 1,000 revolutions per minute for 1 minute. After
washing twice with washing buffer, distilled water was added,
and the sample was incubated at 50°C for 10 minutes. The
sample was then centrifuged at 1,000 rpm for 1 minute, and
DNA was extracted from the supernatants. Both pGEX-4T-1
vector DNA and cloned cDNA were cleaved by Bam HI and
Xho I and ligated with T4 ligase. Recombinant plasmid DNA
was introduced into Escherichia coli DH5 cells. Transformed
E coli DH5 cells were cultured in Luria-Bertani (LB) agar
supplemented with ampicillin for 16 hours. The single colony
on the LB agar was cultured in LB broth for 12 hours. After
minipreparation using the Wizard Plus SV Miniprep DNA
purification system (Promega), followed by treatment with the
restriction enzymes Bam HI and Xho I, we confirmed whether
the cloned cDNA was inserted into the vector.
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Gene expression and purification of recombinant pro-
tein. Transformed E coli was cultured in LB broth until the
absorption density at 600 nm reached 0.45–0.55, as measured
by colorimetry. To induce the expression of recombinant
protein, 1 mM IPTG was added and incubation was continued
for an additional 16 hours at 25°C. After centrifugation, PBS
with proteinase, in an amount up to 1/100 of the cultured
volume, was added. Cells were lysed by sonication on ice.
Triton X-100 was then added to a final concentration of 1%,
and the suspension was mixed gently for 30 minutes to
facilitate solubilization of the proteins.
Supernatant containing the desired protein fused with
glutathione S-transferase (GST) was extracted by centrifuga-
tion at 13,000 rpm for 10 minutes at 4°C. Glutathione–
Sepharose 4B beads were added, and GST fusion protein was
adsorbed onto the beads by shaking incubation for 12 hours.
After the beads were isolated by centrifugation, they were
washed with PBS and with PBS containing proteinase. The
protein absorbed into the beads was isolated by incubation
with elution buffer at room temperature for 30 minutes. Each
50 l of the GST-human -enolase fusion protein, which was
diluted to a concentration of 2 g/ml with carbonate buffer
(pH 9.6), was plated in the microtiter plates and allowed to
stand at 4°C for 18 hours. Glutathione–Sepharose 4B beads
were treated with thrombin protease. Only the required human
-enolase was isolated from the GST fusion protein that had
been absorbed on the beads. We confirmed the purity of this
protein by SDS–polyacrylamide gel electrophoresis (PAGE).
Identification of recombinant protein by gel electro-
phoresis and immunoblotting. After mixing human -enolase
(Polysciences, Warrington, PA) and the purified recombinant
human -enolase with the same amount of sample buffer, the
samples were loaded into the wells of a 10% polyacrylamide
gel and subjected to electrophoresis at a fixed electric current
for 45–90 minutes. The separated gel was transferred to a
nitrocellulose membrane, and the membrane was washed
with PBST and incubated overnight at 4°C in blocking buffer.
The membrane was then incubated overnight at 4°C (with
gentle agitation) with IgM derived from the sera of normal
controls, BD patients, and other rheumatic disease patients,
diluted 1:50 with primary antibody dilution buffer. Goat
anti-human -enolase antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) was used as a positive control at a dilution of
1:100. After washing 3 times with PBST, the membrane was
incubated at room temperature for 2 hours with peroxidase-
conjugated goat anti-human IgM. Diaminobenzidine contain-
ing 30% H2O2 was then added, and the membrane was
incubated at 37°C for 10 minutes.
Dot-blotting was performed to identify the subclass of
the immunoglobulin that on Western blotting appeared to
react with human -enolase. Each 3 l of recombinant
-enolase, which was diluted to a concentration of 7 g/l with
carbonate buffer (pH 9.6) was dropped onto a nitrocellulose
membrane, the membrane was washed with PBST, and then
incubated overnight at 4°C in blocking buffer. Blots were cut
from the membrane and incubated with IgM or IgG from the
sera of BD patients, diluted 1:50 with primary antibody
dilution buffer, and gently agitated overnight at 4°C. After
washing 3 times with PBST, the membrane was incubated with
peroxidase-conjugated goat anti-human IgM or IgG for 2
hours. Diaminobenzidine containing 30% H2O2 was added,
and the membrane was incubated at 37°C for 10 minutes.
Detection of anti-human -enolase antibodies in BD
sera. An IgM ELISA was performed as described above to
examine the reactivity of purified -enolase with sera from the
40 patients with BD and the 13 patients with other rheumatic
diseases.
Figure 1. A, Immunofluorescence labeling of unfixed HDMECs was performed using IgM from the serum of a normal control subject and an
AECA-positive BD patient. B, Western blot analysis of 2 different Behc¸et’s disease (BD) patient sera and a normal control (NC) serum, using human
dermal microvascular endothelial cells (HDMECs) as substrate. Western blotting showed no specific positive bands in the sera of healthy subjects,
but showed a band between 44 kd and 50 kd of the HDMEC protein in the anti–endothelial cell antibody (AECA)–positive sera of BD patients.
Table 1. Frequency of AECA to HDMEC antigen in sera from
normal subjects and patients with Behc¸et’s disease*
Group
% AECA positive
IgG only IgM only IgG  IgM
Normal subjects (n  40) 0 (0) 0 (0) 0 (0)
Behc¸et’s disease patients
(n  40)
4 (10.0) 15 (37.5) 3 (7.5)
* AECA  anti–endothelial cell antibody; HDMEC  human dermal
microvascular endothelial cell.
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RESULTS
Frequency of antibody against HDMEC antigen
in sera from patients with BD. In the IgM ELISA for
HDMEC antigen, the mean (SD) OD of sera from
normal control subjects (n  40) was 0.084  0.031.
Values higher than 0.177, which is the sum of the mean
OD for normal controls and 3 times the SD, were
considered positive. Eighteen of the 40 BD patients
(45%) had positive results: 15 were positive for IgM
only, and 3 were positive for both IgM and IgG. IgM
antibody was not detected in the other BD patients
(Table 1). The mean OD of sera from the patients with
BD was 0.0278  0.106.
In the IgG ELISA, the mean OD of sera from
normal control subjects (n  40) was 0.091  0.052, and
the mean OD of sera from the 40 BD patients was
0.142  0.176. Seven of the 40 BD patients (17.5%) had
positive results: 4 were positive for IgG only, and 3 were
positive for both IgG and IgM. All sera from the BD
patients were negative for RF, ANA, and ANCA.
Reactivity of circulating antibody to HDMEC on
Western blotting. Fractionated IgM obtained from the
sera of AECA-positive BD patients was found to react
with surface antigen on unfixed HDMECs, by confocal
laser microscopy. These findings were compared with
those in IgM obtained from the sera of healthy control
subjects (Figure 1A).
To identify the protein related to the AECA
positivity in BD patient sera, we performed gel electro-
Figure 2. A, Two-dimensional (2-D) gel electrophoresis of cultured
HDMECs after isoelectric focusing on an 18-cm, pH 3–10, linear
immobilized pH gradient strip, showing 2,000 protein spots. Boxed
area shows protein spots in the range of 44–50 kd. B, On 2-D
immunoblotting, 3–4 protein spots in the range of 44–50 kd reacted
with IgM from an AECA-positive BD patient serum. Inset, Higher
magnification of circled area in panel 2. Panel 1 shows serum from a
normal control subject. Results are representative of 3 separate
experiments using 3 different serum samples. See Figure 1 for other
abbreviations.
Figure 3. A, Peptide fingerprint obtained by mass spectrometry of
HDMEC protein spots that showed a strong positive reaction to
AECA on 2-dimensional immunoblotting. The peaks shown on the
peptide fingerprint correspond to -enolase. TOF  time of flight;
LD  laser desorption. B, Analysis of our protein mass data using the
MS-Fit program (see Patients and Methods for details) showed that
the protein spots possessed 41% identity with the amino acid se-
quences of -enolase having a molecular weight of 47 kd and an
isoelectric point of 7.0. MH  peptide plus H. See Figure 1 for
other definitions.
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phoresis with cultured HDMECs and Western blotting
of sera from normal subjects and BD patients who had
positive results on the IgM ELISA. Western blotting
showed no specific positive bands in the sera of normal
control subjects, but a band of HDMEC protein between
44 kd and 50 kd was identified in AECA-positive sera
from patients with BD (Figure 1B).
Isolation and identification of the specific anti-
gen reacting with AECA, using the proteomics method.
About 2,000 protein spots were observed on 2-D gel
electrophoresis of cultured HDMECs after isoelectric
focusing on the 18-cm, pH 3–10, linear IPG strip (Figure
2A). Two-dimensional immunoblotting of IgM obtained
from the sera of AECA-positive BD patients showed
3–4 protein spots of 44–50 kd (Figure 2B). These spots
were removed and examined by mass spectrometry, and
a peptide fingerprint was obtained (Figure 3A). Using
the MS-Fit program provided by UCSF (NCBI scanning
algorithm), we found that 7 of 17 peptides coincided
with human -enolase (within 30 ppm) and that the
protein spots showed a 41% sequence homology with
the amino acid sequences of -enolase (Figure 3B).
Although their isoelectric points and molecular weights
were a little different, all spots were finally identified as
47-kd human -enolase (2-phospho-D-glycerate hydro-
lase) with an isoelectric point of 7.0.
Gene cloning of -enolase in HDMECs. After
isolating whole RNA from cultured HDMECs, we per-
formed RT-PCR on the -enolase, using the identified
sequence of human -enolase from GenBank, and iden-
tified the cDNA of -enolase at 1.3 kbp (Figure 4A).
The recombinant plasmid DNA was obtained from a
minipreparation of transformed E coli by subcloning of
-enolase. We confirmed the vector (4,969 bp) and
inserted double-stranded DNA (1,305 bp) into the plas-
mid (Figure 4B).
Expression and purification of recombinant
-enolase. Protein expression was stimulated with IPTG,
and a highly expressed recombinant protein was puri-
fied. Following SDS-PAGE, only 1 band of GST-human
-enolase fusion protein (75 kd) was observed (Figure
5A). After thrombin treatment of the GST fusion pro-
tein, SDS-PAGE revealed a single band of 47 kd recom-
binant human -enolase produced by gene cloning (Fig-
ure 5B).
Reactivity of BD sera with recombinant human
-enolase. Immunoblotting with recombinant human
-enolase was performed to examine its reactivity with
sera from patients with BD. AECA-positive IgM ob-
tained from the sera of patients with active BD and from
the sera of patients with WG reacted strongly with
recombinant human -enolase (Figure 6A). Sera from
normal controls, RA patients, and SLE patients showed
negative results. Only 1 BD serum, which was AECA-
negative by IgM ELISA, reacted weakly with human
-enolase (data not shown).
Western blotting was performed to determine the
reactivities of BD patient sera to enolase isoforms. BD
patient sera that were positive for anti–-enolase anti-
body did not react with human -enolase (Figure 6B).
On dot-blotting, reactivity to human -enolase was
detected only in the IgM-positive group. No positive
Figure 4. A, Results of reverse transcription–polymerase chain reaction (RT-PCR) of human dermal microvascular
endothelial cell (HDMEC) -enolase. Total RNA of HDMEC was isolated, and primers were designed based on the
coding sequence for human -enolase. Bam HI and Xho I restriction sites were placed at the respective primer terminals
to facilitate subcloning of the PCR product into the pGEX-4T-1 expression vector. B, Both pGEX-4T-1 vector DNA and
-enolase cDNA were cleaved by Bam HI and Xho I and then ligated with T4 ligase. Recombinant plasmid DNA was
introduced into Escherichia coli DH5 cells. To confirm the introduction of the recombinant plasmid DNA into E coli,
we performed a minipreparation. We confirmed the vector (4,969 bp) and inserted double-stranded DNA (1,305 bp)
within the plasmid by treating recombinant plasmid DNA with the restriction enzymes Bam HI and Xho I.
2030 LEE ET AL
reaction was observed with sera from the IgG-positive
group (Figure 7).
Specific positive signals against recombinant hu-
man -enolase were detected by IgM ELISA of serum
samples from 15 of the 40 BD patients (37.5%). Fifteen
of the 18 patients (83.3%) whose sera showed positive
reactivity to HDMEC antigen in the previous IgM
ELISA showed positive reactivity (Table 2). Anti–-
enolase antibodies in sera from patients with other
systemic rheumatic diseases (6 with RA, 5 with SLE, and
2 with WG) were also screened by IgM ELISA. One of
the 6 RA sera (16.7%) and both of the WG sera (100%)
reacted with the human -enolase. However, none of the
5 SLE sera showed reactivity.
DISCUSSION
Although AECAs have been detected in a variety
of inflammatory diseases, there are a few reports of the
Figure 5. A, Polyacrylamide gel electrophoresis of purified glutathione S-transferase (GST)–human -enolase fusion protein
produced by gene cloning. GST (28 kd) obtained from Escherichia coli transformed with vector only was used as a control. Lane
m, Marker; lane 1, bead after extraction of GST; lane 2, extracted GST; lane 3, bead after extraction of GST-enolase; lane 4,
extracted GST-enolase. B, Polyacrylamide gel electrophoresis of human -enolase produced by treatment with thrombin. After
thrombin treatment, a single band of recombinant human -enolase was isolated from the GST fusion protein adsorbed on
glutathione–Sepharose 4B beads. Lane m, Marker; lane 1, purified GST; lane 2, purified -enolase identified at 47 kd after
thrombin treatment.
Figure 6. A, Reactivity of serum AECAs from BD patients to purified -enolase on immunoblotting. AECA-positive IgM from the sera of patients
with active BD (lanes 2, 3, and 4) and Wegener’s granulomatosis (lanes 7 and 8) reacted strongly with purified -enolase on immunoblotting. Normal
control sera (lanes 5 and 6), rheumatoid arthritis patient sera (lanes 9 and 10), and systemic lupus erythematosus patient sera (lanes 11 and 12) did
not react with -enolase. Goat anti–-enolase antibody (lane 1) was used as a positive control. B, Immunoreactivities of sera from BD patients
against -enolase (panel 1) and -enolase (panel 2) isoforms. Recombinant human -enolase and human -enolase were separated on 10% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis gels, transferred onto the membrane, and probed with a BD serum sample containing
anti–-enolase antibodies (1:100 dilution). See Figure 1 for definitions.
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association of AECA with the clinical manifestations of
vasculitis. It has been shown that when vasculitis symp-
toms improve in patients with RA, AECA titers tend to
decrease (15). Moreover, high titers of AECA in pa-
tients with SLE are associated with an active lesion of
the kidney and vasculitis, and it has therefore been
suggested that the AECA titer could be used as a
measure of renal involvement (16).
Microvascular endothelial cells carry a specific
antigen profile that is quite different from the profiles of
the large vessels (17,18). In BD, vasculitis mainly in-
volves capillaries and small vessels (2,3). Direct immu-
nofluorescence of the lesions of BD patients mainly
shows deposition of immunoglobulin on the walls of
small veins (19). One study reported a higher prevalence
of AECA when sera from BD patients were tested
against microvascular endothelial cells as compared with
human umbilical vein endothelial cells as the substrate
(8). This finding provided the rationale for choosing
HDMECs for the present experiments.
AECA-positive BD patients have a significantly
higher frequency of active ocular lesions and acute
thrombosis than do AECA-negative BD patients (7,8).
We have also previously demonstrated that AECA-
positive BD patients have a higher frequency of throm-
bophlebitis than do AECA-negative BD patients (20).
Histopathologically, BD has a characteristic vas-
culitis, presenting as an infiltration of CD4 T lympho-
cytes around the vessels (21). Pretreatment of human
endothelial cells with biologic response modifiers, such
as interleukin-1 (IL-1) and tumor necrosis factor 
(TNF), leads to an increase in the expression of
intercellular cell adhesion molecule 1 (ICAM-1), vascu-
lar cell adhesion molecule 1, and E-selectin molecules
and, consequently, to an increase in the adhesion of T
lymphocytes (14,22). In a previous study, we found that
AECA-positive sera from BD patients led to changes in
the expression of adhesion molecules on the cell surface
of HDMECs and promoted the adherence of T lympho-
cytes to HDMECs and, thus, initiated or amplified
inflammatory vascular injury (10). Our findings also
suggested that IgM AECAs could play a pathogenetic
role in BD by activating EC directly, and not via the
production of TNF or IL-1 by HDMECs. In addition,
as a signal transduction pathway, extracellular signal–
regulated kinases 1 and 2 were involved in the expres-
sion of ICAM-1 on HDMECs stimulated by IgM AECA
(23).
AECA has been detected at various frequencies
in several diseases, but few studies have characterized
the surface antigens against AECA. Moreover, there
have been no other reports elucidating the antigens
against AECA in BD. The human genome was com-
pletely sequenced recently, and as a result, many studies
analyzing the function of various human genes are now
Figure 7. Dot-blots of human -enolase of HDMECs from Top,
normal control (NC) sera and goat anti-human -enolase antibody
(positive control [PC]), A, IgG-negative, IgM-negative sera from 2
representative BD patients, B, IgG-positive, IgM-negative sera from 2
BD patients, C, IgG-negative, IgM-positive sera from 2 BD patients,
and D, IgG-positive, IgM-positive sera from 2 BD patients. Samples
were treated with peroxidase-conjugated goat anti-human IgG (panels
1, 2, 5, 6, 9, 10, 13, and 14) or IgM (panels 3, 4, 7, 8, 11, 12, 15, and 16),
and then tested by enzyme-linked immunosorbent assay for IgG or
IgM antibody reactivity to HDMEC antigen. See Figure 1 for other
definitions.
Table 2. Frequency of autoantibodies to recombinant human
-enolase purified from cultured human dermal microvascular endo-
thelial cells obtained from normal subjects, patients with Behc¸et’s
disease, and patients with other rheumatic diseases
Group
No. of
subjects
No. (%) positive
for anti–-enolase
antibody
Normal control subjects 40 0 (0)
Behc¸et’s disease patients 40 15 (37.5)
Patients with other rheumatic diseases
Rheumatoid arthritis 6 1 (16.7)
Systemic lupus erythematosus 5 0 (0)
Wegener’s granulomatosis 2 2 (100)
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in progress. Proteomics is the most suitable method for
these studies, because proteomics can analyze proteins
by electrophoresis, and these results can be analyzed by
several methods that identify the protein (24–26).
In this study, we produced an HDMEC protein
map with 2,000 protein spots on 2-D electrophoresis
and an 18-cm IPG strip. We observed that many protein
spots produced by BD patient sera, which on the 2-D
immunoblot were between pH 5.0 and pH 8.0 (isoelec-
tric point) and 44–50 kd, reacted with AECA-positive
serum. Using the peptide fingerprint of the protein spot
obtained by mass spectrometry, we were able to com-
pare the protein with human -enolase and found that 7
of 17 peptides coincided within 30 ppm. Due to the high
coincidence of 41% of the amino acid sequences, we
were able to conclude that the protein reacting with
AECA was a human -enolase of molecular weight 47
kd and of isoelectric point 7.0. Initially, we expected that
the protein coinciding with AECA would be a previously
unidentified protein. However, the protein was identi-
fied as -enolase, which has a known DNA sequence.
Consequently, by making use of its known DNA se-
quence, it was not difficult to separate and refine the
human -enolase using gene engineering.
The glycolytic enzyme -enolase is a homodimer
of 47–48 kd. There is 90% homology among the
-enolases of mammals (27). The -enolase enzyme
catalyzes the dehydration of 2-phosphoglycerate to
phosphoenolpyruvate and is usually found in the cyto-
plasm. It exists as a multienzyme complex with other
glycolytic enzymes, such as pyruvate kinase, phospho-
glycerate mutase, muscle creatine kinase, and aldolase,
in the cytoplasm (28,29). Although the mechanisms of
-enolase expression in the cell membrane are not clear,
enolase is expressed on the cell surface after exposure to
an inflammatory stimulus. Enolase functions as the
plasminogen receptor on the surface of various cells,
such as epithelial cells, endothelial cells, and hematopoi-
etic cells. The consequent binding of plasminogen to
-enolase plays a crucial role in fibrinolysis. The role of
this enzyme in systemic or invasive autoimmune disease
was recently reported (30). Certain properties of
-enolase, especially those related to surface expression
and plasminogen binding, indicate that enolase may play
an important role in the initiation of the disease process
by modulating the pericellular and intravascular fibrino-
lytic system.
Antibodies against -enolase have been found in
various inflammatory and immune disorders, such as
cancer-associated retinopathy, ANCA-positive vasculi-
tis, inflammatory bowel disease, discoid lupus erythem-
atosus, SLE, systemic sclerosis, endometriosis, primary
membranous nephropathy, mixed connective tissue dis-
ease, and in autoimmune liver diseases (27,30,31). In
SLE with nephritis, mixed cryoglobulinemia, and diffuse
systemic sclerosis, antienolase antibodies react readily
with renal and endothelial cell antigens, which express
abundant -enolase and, thus, induce injury to those
cells (27). The anti–-enolase antibodies in the sera of
patients with ANCA-positive vasculitis and inflamma-
tory bowel disease react with antigens in the cytoplasm
of neutrophils. In the present study, we found that
antibodies against HDMEC -enolase were present in
37.5% of sera from 40 patients with BD. We also found
that antibodies against HDMEC -enolase are present
in patients with other systemic rheumatic diseases. Thus,
the antibody response to HDMEC -enolase does not
seem to be restricted to BD.
However, ELISA showed that the IgM antibody
response to HDMEC -enolase was present only in the
sera of BD and WG patients, and not in the sera of RA
and SLE patients. Furthermore, all BD patients with
anti–-enolase antibodies were negative for RF, ANA,
and ANCA, a finding that is inconsistent with the
common antibody profiles observed in other rheumatic
diseases. We might well conclude that this antibody
response found in the sera of BD patients might be
useful for the diagnosis of BD, since at present, there is
no definitive diagnostic test for BD.
Three isoforms of enolase that display tissue-
specific distributions have been described. Beta-enolase
is found in skeletal and cardiac muscles, -enolase is
expressed in neural tissue, and -enolase, the embryonic
form, is ubiquitous, although it is most highly expressed
in the kidney and thymus (32). Beta-enolase and
-enolase share 83% homology with -enolase. De-
spite the high degree of homology among the 3 enolase
isoforms, the antibodies react only with the  isomer,
which suggests that these antibodies recognize a unique
epitope on -enolase (33,34). In the present study, BD
patient sera that were positive for anti–-enolase anti-
body did not react with human -enolase. These results
suggest that antibodies from BD patients react with a
specific epitope structure of human -enolase.
Several previous reports have suggested that in
autoimmune diseases, AECA is directed against class I
and class II major histocompatibility complex (MHC) or
ABO blood group antigens (35,36). However, antibodies
against the MHC antigen in normal persons and in some
autoimmune disease patients are often observed only
during pregnancy or following transfusion. Yet, in the
present study, many male patients were positive for this
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antibody, and there was no history of transfusion or
pregnancy among any of the antibody-positive BD pa-
tients. Previous studies have shown higher IgM positivity
compared with IgG positivity for AECA in BD (20), and
direct immunofluorescence has shown a predominance
of IgM class among the immunoglobulins deposited in
the venular walls of BD lesions (19,37). The present
study also showed that the reactivity to HDMEC
-enolase was detected only in IgM-positive BD sera.
These results suggest an important role for IgM class
AECAs in the pathogenesis of vasculitis in BD.
The presence of -enolase on the surface of
streptococci may play a crucial role in the induction of
autoimmune disease caused by streptococci (38). Serum
samples from patients with acute rheumatic fever con-
tain elevated levels of antibodies that react with both
streptococcal and human -enolase. Also, Hsp48, one of
the heat-shock proteins (HSPs), was identified as
-enolase (39). Because HSPs are immunogenic mole-
cules and can be expressed on cell membranes, their role
in autoimmune and inflammatory diseases has been
examined. A cellular immune response of T cells and a
humoral response with the production of antibodies
against HSP have been observed to occur in the course
of those diseases (40). Autoantibodies may bind to the
enolase on the surface of neutrophils and interfere with
phagocytosis. Human enolase is expressed on the im-
mune cell surface after an inflammatory stimulus, and it
may react with antienolase antibodies. Generally, self-
tolerance prevents an autoimmune response, but if this
fails, the reaction of the enolase on the surface of
immune cells with antibody may lead to opsonization or
cell destruction, an increased inflammatory reaction,
and tissue damage. Moreover, the high homology be-
tween streptococcal enolase and human enolase may
facilitate the initiation and development of autoimmune
reactions.
We cannot describe the precise role of -enolase
in the pathogenesis of BD, nor can we explain the
significance of the existence of antibody to -enolase in
the sera of BD patients. However, we believe that this
antigen can be used as a marker of BD. This is the first
study to show that autoantibodies to the -enolase of
HDMEC are present in the sera of BD patients. Possible
explanations for the role of -enolase in BD include the
histopathologic features of vasculitis, frequent retinal
involvement, frequent reports of preceding bacterial
infections (e.g., Streptococcus), the role of HSPs, and
positive reactivity to ANCA. Thus, further studies on the
relationship between -enolase and the pathogenesis of
BD may yield important information about its pathogen-
esis. Moreover, it is hoped that our findings might aid in
the development of new treatments for BD and be of
value in studies of other autoimmune diseases in which
vasculitis is a component. Further studies are necessary
to elucidate the roles of this protein and circulating
autoantibodies in BD, to determine the differences
between BD and other autoimmune diseases in which
vasculitis is a component, and to establish the role of
Streptococcus in the pathogenesis of BD.
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